On June 25, Bio-Techne surged 19.1% in regular trading, trading at $70.22 per share, with turnover of $8.52 billion. The rally was driven by the announcement that German conglomerate Merck KGaA has signed a definitive agreement to acquire Bio-Techne at $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.

The deal follows pressure from activist investor Ananym Capital Management, which had previously sent a letter to Bio-Techne's board urging a strategic review including a potential full sale to a larger industry player. Merck KGaA stated the acquisition is expected to immediately boost sales growth and EBITDA margins, while consolidating its leadership position in the fast-growing life sciences market. A Merck executive noted the transaction is expected to generate approximately 500 million euros in one-time costs.

Following the announcement, Baird raised its price target on Bio-Techne from $49 to $73, maintaining a Neutral rating. The stock's current trading price remains slightly below the $73 offer price, reflecting standard deal-closing risk discount.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)